[go: up one dir, main page]

BRPI0516814A - usos do ácido 2(r,s)-d-ribo-(1',2',3',4'-tetrahidroxibutil)tiazolidina-4( r)-carboxilìco(ribcys) e métodos terapêuticos - Google Patents

usos do ácido 2(r,s)-d-ribo-(1',2',3',4'-tetrahidroxibutil)tiazolidina-4( r)-carboxilìco(ribcys) e métodos terapêuticos

Info

Publication number
BRPI0516814A
BRPI0516814A BRPI0516814-7A BRPI0516814A BRPI0516814A BR PI0516814 A BRPI0516814 A BR PI0516814A BR PI0516814 A BRPI0516814 A BR PI0516814A BR PI0516814 A BRPI0516814 A BR PI0516814A
Authority
BR
Brazil
Prior art keywords
tetrahydroxybutyl
ribo
thiazolidine
ribcys
therapeutic methods
Prior art date
Application number
BRPI0516814-7A
Other languages
English (en)
Inventor
Herbert T Nagasawa
Original Assignee
Bioceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioceuticals Inc filed Critical Bioceuticals Inc
Publication of BRPI0516814A publication Critical patent/BRPI0516814A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

USOS DO áCIDO 2(R,S)-D-RIBO-(1',2',3',4'- TETRAHIDROXIBUTIL)TIAZOLIDINA-4(R)-CARBOXILìCO (R~ IB~Cys) E MéTODOS TERAPêUTICOS. A presente invenção refere-se ao fornecimento de um método terapêutico que compreende o tratamento de um mamífero sujeito a hipoxia com uma quantidade de 2(R,S)-D-ribo-(1',2', 3' ,4'-tetrahidroxibutil)tiazolidina-4(R)-carboxílico (RibCys) ou um sal farmaceuticamente aceitável do mesmo eficaz na manutenção, restabelecimento ou aumento dos níveis de ATP e dos níveis de glutationa (GSH) no dito tecido.
BRPI0516814-7A 2004-11-17 2005-11-16 usos do ácido 2(r,s)-d-ribo-(1',2',3',4'-tetrahidroxibutil)tiazolidina-4( r)-carboxilìco(ribcys) e métodos terapêuticos BRPI0516814A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/990,933 US20060105972A1 (en) 2004-11-17 2004-11-17 Method to enhance delivery of glutathione and ATP levels in cells
PCT/US2005/041458 WO2006055597A1 (en) 2004-11-17 2005-11-16 Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells

Publications (1)

Publication Number Publication Date
BRPI0516814A true BRPI0516814A (pt) 2008-09-23

Family

ID=35759146

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516814-7A BRPI0516814A (pt) 2004-11-17 2005-11-16 usos do ácido 2(r,s)-d-ribo-(1',2',3',4'-tetrahidroxibutil)tiazolidina-4( r)-carboxilìco(ribcys) e métodos terapêuticos

Country Status (14)

Country Link
US (4) US20060105972A1 (pt)
EP (1) EP1824481B1 (pt)
JP (1) JP2008520681A (pt)
KR (1) KR20070095900A (pt)
CN (1) CN101060840A (pt)
AU (1) AU2005307885B2 (pt)
BR (1) BRPI0516814A (pt)
CA (1) CA2587616C (pt)
DK (1) DK1824481T3 (pt)
EA (1) EA014076B1 (pt)
ES (1) ES2390228T3 (pt)
MX (1) MX2007005835A (pt)
PL (1) PL1824481T3 (pt)
WO (1) WO2006055597A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105972A1 (en) * 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
JP4982755B2 (ja) * 2006-06-27 2012-07-25 国立大学法人 長崎大学 高速液体クロマトグラフィーによる糖及び類縁アルデヒド化合物の絶対配置決定法
US8685951B2 (en) * 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
JP5596779B2 (ja) * 2008-04-02 2014-09-24 バイオエナジー インコーポレイティド 急性心筋梗塞に対する初期対応におけるリボースの使用
TW201202209A (en) * 2010-01-28 2012-01-16 Max International Llc Methods of preparing thiazolidines
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
TW201204267A (en) * 2010-05-24 2012-02-01 Max International Llc Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products
US20140348811A1 (en) * 2011-07-27 2014-11-27 Max International, Llc Compositions comprising sugar-cysteine products
CN107708711A (zh) * 2015-05-22 2018-02-16 艾尔牛奶有限公司 β‑酪蛋白A2和抗氧化能力
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1120033B (it) 1979-10-05 1986-03-19 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente-carnitina adatta per l'alimentazione parenterale
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4647571A (en) 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4719201A (en) * 1985-02-07 1988-01-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia
US4605644A (en) * 1985-02-07 1986-08-12 Regents Of The University Of Minnesota Method for stimulating recovery from ischemia employing ribose and adenine
US4736060A (en) 1985-08-06 1988-04-05 Nippon Rikagakuyakuhin Co., Ltd. Method for optical resolution of DL-cysteine and (R,S)-1-(1-naphthyl) ethylamine
JPS63152325A (ja) * 1986-08-20 1988-06-24 Yamanouchi Pharmaceut Co Ltd 脳虚血症予防治療剤
US4868114A (en) * 1987-08-05 1989-09-19 Regents Of The University Of Minnesota Method for elevating glutathione levels
US5095027A (en) * 1991-02-28 1992-03-10 Clintec Nutrition Co. Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid
US5631234A (en) * 1991-04-15 1997-05-20 Teijin Limited Method for treating ischemia-reperfusion tissue injury
JP2873089B2 (ja) * 1991-04-15 1999-03-24 帝人株式会社 虚血・再灌流組織障害及び不整脈並びに活性酸素・フリーラジカルによる肺障害の予防又は治療剤
US5292538A (en) 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
CA2280093A1 (en) 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
US6730336B2 (en) 1998-01-30 2004-05-04 The Procter & Gamble Co. Fortified beverages with improved texture and flavor impact at lower dosage of solids
US6218366B1 (en) * 1998-06-19 2001-04-17 Bioenergy, Inc. Method for raising the hypoxic threshold
US7153503B1 (en) 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
US6534480B2 (en) * 1999-06-17 2003-03-18 Bioenergy Inc. Compositions for increasing energy in vivo
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6881425B2 (en) 2001-08-31 2005-04-19 Council Of Scientific And Industrial Research Custom made herbal health promotive formulation for females/expectant mothers
US6572899B1 (en) 2002-07-03 2003-06-03 Vitacost.Com, Inc. Memory loss treatment formulation
US7455857B2 (en) 2003-04-08 2008-11-25 Janeel Henderson Energy generating composition
GB0319463D0 (en) 2003-08-20 2003-09-17 Givaudan Sa Compounds
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20060105972A1 (en) * 2004-11-17 2006-05-18 Nagasawa Herbert T Method to enhance delivery of glutathione and ATP levels in cells
US8962058B2 (en) 2005-11-23 2015-02-24 The Coca-Cola Company High-potency sweetener composition with antioxidant and compositions sweetened therewith
BRPI0621321A2 (pt) 2006-02-10 2011-12-06 Mannatech Inc formulações de suplemento dietético de multivitamìnico e multimineral natural para melhor absorção e utilização biológica
US8685951B2 (en) 2007-03-27 2014-04-01 The Board Of Trustees Of The University Of Arkansas Compositions and methods for cytoprotection
WO2010033915A2 (en) 2008-09-19 2010-03-25 Unicity International Inc. Method of controlling blood sugar levels, insulin levels, cholesterol levels, body fat levels, and body weight by administering a nutrient fiber matrix
TW201201712A (en) 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
TW201204267A (en) 2010-05-24 2012-02-01 Max International Llc Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products

Also Published As

Publication number Publication date
AU2005307885A2 (en) 2006-05-26
CA2587616A1 (en) 2006-05-26
DK1824481T3 (da) 2012-09-24
EP1824481A1 (en) 2007-08-29
MX2007005835A (es) 2007-10-08
EA200701017A1 (ru) 2007-10-26
AU2005307885A1 (en) 2006-05-26
CA2587616C (en) 2015-03-17
WO2006055597A1 (en) 2006-05-26
KR20070095900A (ko) 2007-10-01
US20160082029A1 (en) 2016-03-24
JP2008520681A (ja) 2008-06-19
EP1824481B1 (en) 2012-08-29
AU2005307885B2 (en) 2010-12-23
US9144570B2 (en) 2015-09-29
US8501700B2 (en) 2013-08-06
US20130317072A1 (en) 2013-11-28
ES2390228T3 (es) 2012-11-07
EA014076B1 (ru) 2010-08-30
CN101060840A (zh) 2007-10-24
US20090042822A1 (en) 2009-02-12
PL1824481T3 (pl) 2012-11-30
US20060105972A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
Ward et al. Aluminium toxicity and iron homeostasis
Balijepalli et al. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics
Wang et al. Heme oxygenase 2 is neuroprotective against intracerebral hemorrhage
Rump et al. Acetyl-L-carnitine protects neuronal function from alcohol-induced oxidative damage in the brain
Ramasamy et al. The in vivo cardiovascular effects of box jellyfish Chironex fleckeri venom in rats: efficacy of pre-treatment with antivenom, verapamil and magnesium sulphate
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
EA201000441A1 (ru) Водные офтальмологические препараты
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
WO2002002190A3 (en) Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
BR0214772A (pt) sistemas e métodos para o tratamento de pacientes com células lipoaspiradas processadas
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
BRPI0516814A (pt) usos do ácido 2(r,s)-d-ribo-(1',2',3',4'-tetrahidroxibutil)tiazolidina-4( r)-carboxilìco(ribcys) e métodos terapêuticos
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
KR20040078663A (ko) 난청의 치료 방법
BRPI0405732A (pt) Formulações tópicas para tratamento de rosácea
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
BRPI0607536A2 (pt) tratamento de dor
Yorek et al. Effect of Fidarestat and α‐Lipoic Acid on Diabetes‐Induced Epineurial Arteriole Vascular Dysfunction
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR0315170A (pt) Tratamento de superfìcie
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
Badhwar et al. Limitations of ischemic tolerance in oxidative skeletal muscle: perfusion vs tissue protection

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CELLGEVITY, INC. (US)

Free format text: NOME ALTERADO DE: BIOCEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: CELLGEVITY, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 018110047961/RJ DE 08/12/2011.

B25A Requested transfer of rights approved

Owner name: MAX INTERNATIONAL, LLC (US)

Free format text: TRANSFERIDO DE: CELLGEVITY, INC.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]